Cantabio Pharmaceuticals Inc. (CTBO)
OTC PINK OTC PINK Primary Summary
Cantabio Pharmaceuticals Inc. (CTBO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cantabio Pharmaceuticals Inc. ever had a stock split?
Cantabio Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gergely Tóth CEO | OTC PINK Exchange | 13808X203 CUSIP |
| US Country | 451 Employees | - Last Dividend | 20 Jun 2019 Last Split | - IPO Date |
Overview
Cantabio Pharmaceuticals, Inc. is a biotechnology company that is currently in the preclinical stage, primarily focusing on the development and commercialization of innovative therapies aimed at treating neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD). By targeting the molecular mechanisms that underlie these conditions, Cantabio is dedicated to discovering treatments that can halt or reverse the progression of these debilitating diseases. Founded in 2009 and headquartered in Palo Alto, California, the company has established a significant collaboration with the Luxembourg Institute of Health to explore the therapeutic potential of targeting the DJ-1 protein in treating immune-associated diseases. Through rigorous research and development, Cantabio Pharmaceuticals seeks to make a substantial impact on improving the lives of patients suffering from PD, AD, and related disorders.
Products and Services
- CB101: DJ-1 Targeting Small Molecule Pharmacological Chaperone for Parkinson's Disease
- CB201: CNS Penetrant Engineered DJ-1 Protein for Parkinson's Disease
- CB301: Tau Protein Targeting Small Molecule Pharmacological Chaperone for Alzheimer's Disease
- CB401: Aß Targeting Small Molecule Pharmacological Chaperone for Alzheimer's Disease
CB101 is one of Cantabio's foremost projects, focusing on a small molecule pharmacological chaperone designed to target DJ-1, a protein associated with the protection of neurons in PD. This innovative approach aims to stabilize DJ-1 and enhance its protective functions, potentially offering a novel treatment strategy for Parkinson's disease by addressing one of its critical pathological mechanisms.
As an extension of its commitment to battling PD, Cantabio is developing CB201, a Central Nervous System (CNS) penetrant, engineered version of the DJ-1 protein. This therapy is intended to supplement the function of endogenous DJ-1 protein in the brain, thereby offering a cutting-edge approach to temper the disease's progression through direct protein supplementation.
In its fight against Alzheimer's disease, Cantabio has introduced CB301, a therapy centered around a small molecule pharmacological chaperone that targets tau protein aggregation. Since tau protein dysfunction and aggregation are key features in the progression of AD, CB301 aims to inhibit these processes, providing a hopeful avenue for treatment that could significantly impact AD management by targeting its core pathological features.
CB401 represents another innovative approach by Cantabio to combat AD through the targeting of amyloid-beta (Aß) aggregation, a hallmark of Alzheimer's pathology. By focusing on this specific molecular target, CB401 seeks to alleviate the symptoms and slow down the progression of AD by preventing the formation of amyloid plaques, thus contributing to a broader strategy against this challenging disease.
